The Advocate Releases First Annual List of ‘Top Pharmaceutical Patient Advocacy Teams’
Janssen, BMS, and Pfizer round out the top three
The Advocate: Supporting the Patient Voice, who provides bench-marking data to the pharma industry, has revealed its first ever list of top overall pharmaceutical patient advocacy organizations. The program’s goal is to keep the patient at the center of all healthcare decision making by elevating the voice of patient advocacy organizations (PAOs).
The ranking of that list was completed by assigning point values for placing within the top five for each of the five stack-ranked categories. The Advocate then pooled the total points earned by each organization to generate the overall scores shown in the graph below.
The Advocate's top pharmaceutical patient advocacy organizations for 2021/2022
In first place with a cumulative score of 23 out of a total 25 points is Janssen, The Pharmaceutical Companies of Johnson & Johnson, followed by Bristol Myers Squibb (BMS) with 16 overall points, and Pfizer rounding out the top three.
“We acclaim our top three overall pharmaceutical advocacy teams and commend runners up: Amgen in fourth overall with 11 points, Eli Lilly in fourth with seven points, Merck in sixth with five points, and AstraZeneca, Sanofi, and AbbVie rounding out the ranks with one point each,” notes Matt Toresco, editor-in-chief of the syndicated market research program. “This was a great year for all organizations involved, and we look forward to bringing forth this metric in future years."
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.
